Human IL-28A/IFN-lambda 2 MAb (Clone 248526) (25 UG)【科瑞奥博】

产品中心

当前位置：首页>产品中心

Human IL-28A/IFN-lambda 2 MAb (Clone 248526) (25 UG)

货号： MAB1587-SP 基本售价： 1467.3 元规格： -

产品信息

概述
货号	MAB1587-SP
别名	interleukin-28A; IFN-lambda 2; IL28A; IL-28A; interferon, lambda 2
全称	Interleukin 28A
反应种属	Human
应用	Neutralization
目标/特异性	Detects human IL‑28A/IFN‑ lambda 2 in direct ELISAs. In direct ELISAs, 83% cross-reactivity with recombinant human (rh) IL-28B/IFN-lambda 3 and no cross-reactivity with recombinant mouse IL-28B/IFN-lambda 3 or rhIL-29/IFN-l1 is observed.
使用方法	Neutralization: Measured by its ability to neutralize IL‑28A/IFN‑ lambda 2 inhibition of EMCV-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The Neutralization Dose (ND₅₀) is typically 0.25-1.0 µg/mL in the presence of 0.1 µg/mL Recombinant Human IL‑28A/IFN‑ lambda 2.
来源	Monoclonal Mouse IgG₁ Clone # 248526
产品组分

性能
供应商	R&D Systems
Entrez Gene IDs	282616 (Human)
应用文献
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. Authors: Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, Lewis-Antes A, Amrute S, Garrigues U, Doyle S, Donnelly R, Kotenko S, Fitzgerald-Bocarsly P J Immunol, 2012;189(6):2735-45. Species: Human Sample Type: Whole Cells Application: Flow
纯化方式	Protein A or G purified from hybridoma culture supernatant
免疫原	Mouse myeloma cell line NS0-derived recombinant human IL‑28A/IFN‑ lambda 2 Val26-Val200 Accession # Q8IZJ0
内毒素水平	<0.10 EU per 1 μg of the antibody by the LAL method.
生物活性	Human
标记	Unconjugated
溶解方法	Reconstitute at 0.5 mg/mL in sterile PBS.
背景	IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11‑13% aa sequence identity) and type I IFN family (15‑19% aa sequence identity) (1‑3). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up‑regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL‑10 receptor beta (IL‑10 R beta ) and a novel IL‑28 receptor alpha (IL‑28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory regions of the target genes. Human IL-28A cDNA encodes a 200 amino acid (aa) residue precursor protein with a 25 aa signal peptide. It shares 94% and 67% aa sequence identity with human IL-28B and human IL-29, respectively.
运输条件	Blue Ice
存放说明	4℃
参考文献	Vilcek, J. (2003) Nature Immunol. 4:8. Sheppard, P. et al. (2003) Nature Immunol. 4:63. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.

参考图片

IL‑28A/IFN‑ lambda 2 Inhibition of EMCV‑induced Cytopathy and Neutralization by Human
IL‑28A/IFN‑ lambda 2 Antibody.

Recombinant Human
IL‑28A/IFN‑ lambda 2 (Catalog #
1587‑IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IL‑28A/IFN‑ lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti‑Human IL‑28A/IFN‑ lambda 2 Monoclonal Antibody (Catalog # MAB1587). The ND₅₀ is typically 0.25‑1.0 µg/mL.